Skip to content
type1.science
Phase 4Not yet recruitingNCT06600776

Ultra-rapid lispro timing in MiniMed 780G

What this study tests

Tel Aviv pilot trial comparing mealtime versus post-meal dosing of ultra-rapid lispro in adults using the MiniMed 780G hybrid closed-loop system.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2024-09-24.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Adults with T1D already using MiniMed 780G with URLi. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet. The registry’s estimated primary completion (2025-09-21) has passed, but no results are posted. That outdated estimate does not establish study completion.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Percentage of time in range 70-180 mg/dL

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]